Oncolytics reports promising cancer trial data but warns of going concern doubt

Filed March 30, 2026 · Period ending December 31, 2025 · ~2 min read

Key Changes

• high

  Company discloses substantial doubt about ability to continue operations beyond 12 months. Cash balance of $5.2M insufficient to fund planned operations; management pursuing additional capital through ATM facility and partnerships with no assurance of success.

  MD&A: Liquidity verify on EDGAR →
• high

  Pelareorep achieved 62% response rate in first-line pancreatic cancer versus 25% historical standard, and 30% response rate in second-line anal cancer versus 13.8% approved treatment. FDA granted Fast Track Designation for colorectal cancer indication based on 33% response rate versus 10% standard-of-care.

  Business: Clinical Results verify on EDGAR →
• high

  Net loss increased to $28.8M in 2025 from $22.8M in 2024. Company raised $14.1M through dilutive equity offerings, increasing shares outstanding from 80M to 108M (35% dilution). Shareholders' equity turned negative to $(3.8)M deficit.

  MD&A: Financial Results verify on EDGAR →